Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.

por Kovatcheva, Marta, Klein, Mary E., Tap, William D., Koff, Andrew
Publicado 2017

ATRX guards against aberrant differentiation in mesenchymal progenitor cells

por Fang, Yan, Barrows, Douglas, Dabas, Yakshi, Carroll, Thomas S, Tap, William D., Nacev, Benjamin A.
Publicado 2023

Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas

por Anderson, Jennifer L., Park, Ann, Akiyama, Ryan, Tap, William D., Denny, Christopher T., Federman, Noah
Publicado 2015

Platelet-derived growth factor receptor-α and -β promote cancer stem cell phenotypes in sarcomas

por Chang, Kevin K., Yoon, Changhwan, Yi, Brendan C., Tap, William D., Simon, M. Celeste, Yoon, Sam S.
Publicado 2018

Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy

por Yoon, Changhwan, Chang, Kevin K., Lee, Jun Ho, Tap, William D., Hart, Charles P., Simon, M. Celeste, Yoon, Sam S.
Publicado 2016

Psychosocial Needs and Preferences for Care among Adolescent and Young Adult Cancer Patients (Ages 15–39): A Qualitative Study

por Avutu, Viswatej, Lynch, Kathleen A., Barnett, Marie E., Vera, Jacqueline A., Glade Bender, Julia L., Tap, William D., Atkinson, Thomas M.
Publicado 2022

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma

por Jones, Robin L., Mo, Gary, Baldwin, John R., Peterson, Patrick M., Ilaria, Robert L., Conti, Ilaria, Cronier, Damien M., Tap, William D.
Publicado 2018

ATRX is a regulator of therapy induced senescence in human cells

por Kovatcheva, Marta, Liao, Will, Klein, Mary E., Robine, Nicolas, Geiger, Heather, Crago, Aimee M., Dickson, Mark A., Tap, William D., Singer, Samuel, Koff, Andrew
Publicado 2017

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma

por Schöffski, Patrick, Bahleda, Rastislav, Wagner, Andrew J., Burgess, Melissa A., Junker, Niels, Chisamore, Michael, Peterson, Patrick, Szpurka, Anna M., Ceccarelli, Matteo, Tap, William D.
Publicado 2023

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmac...

por Zahir, Hamim, Greenberg, Jonathan, Hsu, Ching, Marbury, Thomas C., Lasseter, Kenneth C., Xu, Li‐An, Tap, William D., Healey, John H., Stacchiotti, Silvia, LaCreta, Frank
Publicado 2022

Incidence and Management of Olaratumab Infusion-Related Reactions

por Van Tine, Brian A., Govindarajan, Rangaswamy, Attia, Steven, Somaiah, Neeta, Barker, Scott S., Shahir, Ashwin, Barrett, Emily, Lee, Pablo, Wacheck, Volker, Ramage, Samuel C., Tap, William D.
Publicado 2019

Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients

por Sutton, Charles, Zhang, Yachao, Kim, DaeHee, Yarmohammadi, Hooman, Ziv, Etay, Boas, Franz E., Sofocleous, Constantinos T., Tap, William D., D'Angelo, Sandra P., Erinjeri, Joseph P.
Publicado 2020

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors

por Yin, Ophelia, Wagner, Andrew J., Kang, Jia, Knebel, William, Zahir, Hamim, van de Sande, Michiel, Tap, William D., Gelderblom, Hans, Healey, John H., Shuster, Dale, Stacchiotti, Silvia
Publicado 2020

Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients

por Shurell, Elizabeth, Tran, Linh M, Nakashima, Jonathan, Smith, Kathleen B, Tam, Brenna M, Li, Yunfeng, Dry, Sarah M, Federman, Noah, Tap, William D, Wu, Hong, Eilber, Fritz C
Publicado 2014

FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas

por Benz, Matthias R., Czernin, Johannes, Tap, William D., Eckardt, Jeffrey J., Seeger, Leanne L., Allen-Auerbach, Martin S., Dry, Sarah M., Phelps, Michael E., Weber, Wolfgang A., Eilber, Fritz C.
Publicado 2010

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence

por Klein, Mary E., Dickson, Mark A., Antonescu, Cristina, Qin, Li-Xuan, Dooley, Scott J., Barlas, Afsar, Manova, Katia, Schwartz, Gary K., Crago, Aimee M., Singer, Samuel, Koff, Andrew, Tap, William D.
Publicado 2018

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor

por Yin, Ophelia, Zahir, Hamim, French, Jonathan, Polhamus, Daniel, Wang, Xiaoning, van de Sande, Michiel, Tap, William D., Gelderblom, Hans, Wagner, Andrew J., Healey, John H., Greenberg, Jonathan, Shuster, Dale, Stacchiotti, Silvia
Publicado 2021

Comprehensive genomic profiling of EWSR1/FUS-CREB translocation-associated tumors uncovers prognostically significant recurrent genetic alterations and methylation-transcriptional...

por Dermawan, Josephine K., Vanoli, Fabio, Herviou, Laurie, Sung, Yun-Shao, Zhang, Lei, Singer, Samuel, Tap, William D., Benayed, Ryma, Bale, Tejus A., Benhamida, Jamal K., Dickson, Brendan C., Antonescu, Cristina R.
Publicado 2022

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma

por Madanat-Harjuoja, Laura M., Klega, Kelly, Lu, Yao, Shulman, David S., Thorner, Aaron R., Nag, Anwesha, Tap, William D., Reinke, Denise K., Diller, Lisa, Ballman, Karla V., George, Suzanne, Crompton, Brian D.
Publicado 2022

AI-Radiomics Can Improve Inclusion Criteria and Clinical Trial Performance

por Tomaszewski, Michal R., Fan, Shuxuan, Garcia, Alberto, Qi, Jin, Kim, Youngchul, Gatenby, Robert A., Schabath, Matthew B., Tap, William D., Reinke, Denise K., Makanji, Rikesh J., Reed, Damon R., Gillies, Robert J.
Publicado 2022